Leveraged Finance Fights Melanoma
Over ten years, LFFM has raised over $27 million to advance 21 grants for cutting-edge melanoma research. LFFM’s support of MRA has not only helped improve survivorship for melanoma patients, but has allowed MRA to champion revolutions in immunotherapies, targeted therapies, and novel combinations that are now being used in many other cancer types.
2025 LFFM Event
Check back here by August 15 for the 2025 date and sponsorship opportunities.
Thank you to the 2024 Leveraged Finance Fights Melanoma community for raising record breaking $4 million from over 100 leveraged finance firms, 100% benefitting melanoma research.
Event Chairs: Clare Bailhé (MidCap Financial), Brendan Dillon (Veritas Capital), Kerry Dolan (Brinley Partners), Lee Grinberg (Elliott Management), Jason Kanner (Kirkland & Ellis), Matt Manin (Apollo), Eliza McDougall (White & Case), Erwin Mock (Thoma Bravo), George Mueller (KKR), Geoff Oltmans (Silver Lake), Kevin Pluff (HPS Investment Partners), Jeff Rowbottom (General Atlantic Credit), Ian Schuman (Latham & Watkins), Cade Thompson (KKR), Brian Steinhardt (Simpson Thacher & Bartlett), Trevor Watt (Hellman & Friedman), & Eric Wedel (Paul, Weiss, Rifkind, Wharton & Garrison).
About LFFM: Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities who come together to fight melanoma, the deadliest form of skin cancer. Some of the most prominent names in the industry —Carl Icahn, Michael Milken, Leon Black, Henry Kravis and Howard Marks—have been featured.
The annual event raises critical funds for melanoma research and awareness on skin cancer prevention. Founded in 2011 by Jeffrey Rowbottom and Brendan Dillon—both of whom have been impacted by a melanoma diagnosis— the LFFM event has raised $27 million that goes directly to research.
Advances in melanoma research supported by MRA have changed the landscape dramatically for patients, with 15 of the 17 treatment options coming to market since the event’s kick-off. These advances have created a ripple effect across the field of oncology. Drugs first approved in melanoma are now being tested in more than 30 cancers.
2024 LFFM Sponsors:
